Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Slides:

Advertisements

Similar presentations

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Advertisements

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

In vivo responses of AMLMLL to ATRi.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Abundance of non–islet-specific CTLs at islets is immune-suppressive.

T-bethi MP cells produce IFN-γ in response to IL-12.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Fig. 1. MSCs undergo in vivo apoptosis after infusion without affecting immunosuppression. MSCs undergo in vivo apoptosis after infusion without affecting.

ONC201 activates the ISR. ONC201 activates the ISR. (A) Western blotting analysis for ATF4, CHOP, ATF3, and TRB3 on lysates from HCT116 cells cultured.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 1. Iontophoretic devices used for the delivery of cytotoxic agents to solid tumors. Iontophoretic devices used for the delivery of cytotoxic agents.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

Vaccine MN confer protective innate and adaptive immunity.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 3. Increased expression of exhaustion markers and apoptosis markers on CAR8 cells in the presence of TCR antigen. Increased expression of exhaustion.

Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.

Fig. 1 Inbred mouse strains carrying monoclonal tumors display a symmetrical yet disparate response to ICB, associated with a distinctive gene signature.

Fig. 1 Neu1−/− fibroblasts have characteristics of myofibroblasts.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 2 Inflammatory pathways with STAT1 as a key regulator are enriched in ICB responsive tumors in mouse models and patients. Inflammatory pathways with.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective breast tumors. E-cadherin synthetic lethal effects operate in vivo in E-cadherin–defective.

Fig. 4 Activation of mitochondrial apoptosis pathway by n-HA.

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Fig. 1. Matrix stiffness sensitizes myofibroblasts to apoptosis induced by inhibition of their mechanotransduction pathways. Matrix stiffness sensitizes.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

by Samuel J. Taylor, Johanna M. Duyvestyn, Samantha A. Dagger, Emma J

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Nanoimmunotherapy production scale-up and evaluation in Apoe−/− mice

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

PD and efficacy of AZD4785 in KRAS mutant lung cancer xenograft models

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Fig. 2 NDR2-deficient mice are more vulnerable to RNA viral infection.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 3. Human liver tissue seed graft function.

Targeting p53-dependent stem cell loss for intestinal chemoprotection

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 2. Human liver tissue seed grafts expand after host liver injury.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Fig. 6 The combined therapeutic efficacy of N-pepABS and low dose of Dox on MDA-MB-231 xenografts. The combined therapeutic efficacy of N-pepABS and low.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 5 In vivo autologous self-targeting efficacy of DR-KO tumor cells co-engineered with a secretable DRL and a suicide system. In vivo autologous self-targeting.

Fig. 6 KHK-A–mediated p62 S28 phosphorylation promotes hepatocellular tumorigenesis and is associated with clinical aggressiveness of human HCC. KHK-A–mediated.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Fig. 6 Pharmacologic alterations of β-AR signaling regulate cardiomyocyte abscission and endowment. Pharmacologic alterations of β-AR signaling regulate.

Fig. 8 Immune correlates of protection.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

Fig. 3. Effects of SFN in mice with diet-induced diabetes.

CCR6 is dispensable for expansion of innate TCRαβ+ cells in oral candidiasis. CCR6 is dispensable for expansion of innate TCRαβ+ cells in oral candidiasis.

Correlation of TAN phenotypes and TIL effector function.

Presentation transcript:

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. (A) Timeline of the experimental setup for (B) and (C). (B) Hep3B xenografts were treated with vehicle, M1 virus (5 × 105 PFUs, intravenously), EerI (2 mg/kg, intraperitoneally), or a combination. Data are mean tumor volume ± SD (eight mice per group). ***P < 0.001 for M1-EerI combination versus single agents. (C) Huh 7 xenografts were treated with vehicle, M1 virus (5 × 105 PFUs, intravenously), EerI (2 mg/kg, intraperitoneally), or a combination. Data are mean tumor volume ± SD (eight mice per group). ***P < 0.001 for M1-EerI combination versus single agents. (D) Timeline of the experimental setup for (E). (E) Kaplan-Meier survival curve of mice bearing Hep3B tumors treated with vehicle, M1 virus (1 × 106 PFUs, intravenously), EerI (2 mg/kg, intraperitoneally), or a combination. CTL, n = 7; EerI, n = 7; M1, n = 8; M1 + EerI, n = 8. ***P < 0.001, log-rank with Holm-Sidak multiple comparisons. (F) Representative images of livers from each group in (E) at day 15. Dashed blue lines represent tumor areas. (G) Timeline of experimental setup for (H). (H) Kaplan-Meier survival curves of immunocompetent mice bearing Hepa1-6 tumors treated with vehicle, M1 virus (1 × 106 PFUs, intravenously), CB-5083 (25 mg/kg, orally), or a combination. CTL, n = 6; CB-5083, n = 5; M1, n = 6; M1 + CB-5083, n = 6. ***P < 0.001, log-rank with Holm-Sidak multiple comparisons. (I) Representative images of livers from each group in (H) at day 15. Dashed blue lines represent tumor areas. (J) Tumor tissues from (F) were evaluated through immunohistochemistry for Ki-67 (a marker of proliferation), IRE1α (a marker of the UPR pathway), p-JNK (a marker of ER stress–induced apoptosis), cleaved caspase-3, and E1 (structural protein of M1 virus). N, nontumor area; T, tumor area. Scale bar, 50 μm. (K) HCC tissues from five patients were treated with vehicle, EerI (10 μM), M1 (2 × 106 PFUs), or a combination for 96 hours, and cell viability was assessed. (L) Amounts of VCP protein in five patients. P, patient. Quantification (indicated by the numbers at the top) was performed using ImageJ software. (M) Correlation of cytotoxicity and relative VCP expression. r is the Pearson correlation coefficient. Haipeng Zhang et al., Sci Transl Med 2017;9:eaam7996 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works